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Apolipoprotein 4 (apoE, protein; APOE , gene) allele
is the most important genetic risk factor for develop-
ment of Alzheimer’s disease and is also associated
with poor outcome after brain injury. Although the
mechanisms underlying this susceptibility are cur-
rently unknown, recent experimental evidence sug-
gests that APOE genotype may influence activity in
the endocytic pathway of neurons. This study deter-
mined whether alterations in the endocytic pathway
occurred in medial temporal lobe sections after brain
injury because of cardiorespiratory arrest and
whether these alterations were influenced by APOE
genotype. Antibodies to two proteins involved in en-
docytosis, rabaptin-5 and rab4, were used as markers
of endocytic pathway activity. Alterations in immuno-
reactivity were examined in medial temporal lobe
sections in the postmortem brain of patients who
experienced an episode of global ischemia and in
controls. After global ischemia there was a marked
increase in immunoreactivity of both endocytic mark-
ers, rabaptin-5 and rab4, in neurons, and to a lesser
extent in glia compared to controls. Furthermore,
possession of an APOE 4 allele was associated with
specific alterations in the endocytic pathway. After
global ischemia, there was no influence of APOE ge-
notype on the extent of rabaptin-5 immunoreactivity.
However, there was a statistically significant influ-
ence of APOE genotype on the extent of rab4 immu-
noreactivity in response to global ischemia. These
results indicate marked alterations in the endocytic
pathway after global ischemia that are dependent on
APOE genotype. This may underlie the important in-
fluence of APOE genotype on brain injury and dis-
ease. (Am J Pathol 2003, 162:273–281)
Endocytosis is an intracellular trafficking process whereby
macromolecules are transported from the plasma mem-
brane to the cellular cytosol in a series of intracellular com-
partments or vesicles. In neurons, the endocytic pathway is
involved in processes common to various cell types such as
the uptake of nutrients and trophic factors. In addition, neu-
ronal endocytosis is intimately associated with events after
neurotransmitter release including the internalization, deg-
radation, and recycling of plasma membrane receptors and
their associated ligands.
Early and late endosomes and lysosomes comprise
the group of intracellular membrane-bound compart-
ments also known as the central vacuolar system. The
early endosome receives receptor/ligand complexes
from internalized clathrin-coated pits and is the first major
sorting station in the pathway.1 From the early endosome,
molecules that have been sequestered by neurons have
three major fates: recycling back to the plasma mem-
brane, particularly receptors; transport to intracellular
membranous organelles for further sorting and distribu-
tion; and degradation by the lysosomal proteolytic en-
zymes.2–4
The various pathways and stages of endosomal traf-
ficking are regulated by numerous proteins, with the Rab
enzymes particularly prominent.1,4–7 The rab proteins are
a group of GTPases that localize to specific components
of the endocytic machinery and regulate distinct stages
of endocytic trafficking. Three proteins whose actions
have been well documented are rab4, rab5, and rab7.
Rab4 associates with recycling endosomes and is re-
quired for efficient transport of molecules back to the
plasma membrane.8 Rab5, in contrast, localizes to early
endosomes and is involved in the internalization stage of
endocytosis.9 Rab7 is essential for the trafficking of mol-
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ecules from early to late endosomes.10 In addition, the
role of rabaptin-5, an effector of rab5 that is recruited to
early endosomes during periods of endocytic activation,
has also been documented.7
The endocytic pathway is a key point of convergence
of several proteins implicated in Alzheimer’s disease
(AD) pathophysiology, such as amyloid precursor pro-
tein, amyloid- (A), and apolipoprotein E (apoE, protein;
APOE, gene). In view of this, there has been increasing
interest in the role of endocytic alterations in neuronal
dysfunction. Observations in AD postmortem brain have
indicated that there is endocytic activation and up-regu-
lation of lysosomal activity.11,12 Using an antibody to
rab5, it was shown that there is an increase in the number
of rab5 immunoreactive early endosomes, and a marked
enlargement of these endosomes in neocortical pyrami-
dal neurons. The size and number of early endosomes is
believed to be proportional to the rate of endocytic up-
take,13–15 and therefore, the observations above would
suggest an increase in endocytic uptake. Furthermore,
these alterations precede the appearance of AD pa-
thology, such as amyloid deposits.12 It has also been
shown that rabaptin-5, a marker of internalization, in-
teracts with neuronal growth-associated protein.16
Growth-associated protein plays an important role in
neuronal plasticity after injury and therefore endosomal
alterations may also be involved in the plastic response
to neuronal insult.
ApoE is a polymorphic protein that exists as three
major isoforms; E2, E3, and E4, encoded by the alleles
2, 3, and 4. Possession of one or more copies of the 4
allele is a major risk factor for late-onset familial and
sporadic AD17 and for poor outcome after head injury.18
Patients with the APOE 3 genotype show a significantly
higher survival rate and increased chance of a favorable
neurological outcome compared to non-APOE 3 individu-
als after cardiopulmonary resuscitation.19 Studies using an-
imal models of cardiac arrest have provided evidence of an
APOE genotype influence. ApoE-deficient mice have in-
creased neuronal damage after global ischemia.20 APOE 4
mice have more extensive neuronal damage and apoE
immunoreactivity after global ischemia compared to APOE
3 mice.21 The mechanisms underlying this susceptibility
remain unclear and as yet alterations in the endocytic path-
way have not been determined.
This study tested the hypothesis that alterations in the
endocytic pathway occur after brain injury and that this is
APOE genotype-dependent. Markers of the endocytic
pathway were examined in postmortem brain from pa-
tients who experienced an episode of global ischemia
because of cardiac arrest and were compared to neuro-
pathologically normal controls. To detect changes in en-
docytic pathway activity we used antibodies to two pro-
teins involved in different stages of endocytosis,
rabaptin-5 and rab4. Rabaptin-5 is a cytoplasmic effector
protein recruited to the membrane of early endosomes
during endocytosis. Rab4 is a protein that localizes to the
membrane of endosomes being transported back to the
cellular plasma membrane.
Materials and Methods
Postmortem Human Brain Tissue
The control and global ischemia groups were matched
for age and male:female ratio. Archival paraffin-embed-
ded blocks of medial temporal lobe were selected from
43 patients who died after an episode of global ischemia
because of cardiorespiratory arrest (27 males, 16 fe-
males; mean age, 50 years). The survival period after the
initial episode of global ischemia ranged from 11 hours to
3 months. Thirty-eight control patients (25 males, 13 fe-
males; mean age, 51 years) without clinical or neuro-
pathological evidence of neurological or psychiatric im-
pairment or cardiovascular disease, were used in this
experiment. APOE genotyping was determined from the
paraffin-embedded brain tissue as previously described
using the polymerase chain reaction/restriction enzyme
analysis technique.22 The success rate for the determi-
nation of APOE genotype was high; APOE genotype was
undetermined in only three control patients. Conse-
quently, 35 controls were used when analyzing the influ-
ence of APOE genotype. The frequency of the APOE 4
allele was similar in the control and global ischemia
groups. In the control group, 24 individuals were without
an 4 allele (mean age, 52 years) and 11 individuals had
at least one 4 allele (mean age, 49 years); in the global
ischemia group, 28 cases were without an e4 allele
(mean age, 52 years) and 15 cases had an 4 allele
(mean age, 49 years). This study was approved by the
ethics committee of the Southern General Hospital.
Rabaptin-5 and Rab4 Immunohistochemistry
Paraffin-embedded sections were dewaxed in an oven at
60°C for 40 minutes, and in histoclear (2  10 minutes)
followed by dehydration in absolute alcohol (2  10
minutes). Endogenous peroxidase was eliminated by in-
cubating the sections with 0.5% hydrogen peroxide for
30 minutes followed by washes in running water for 40
minutes and phosphate-buffered saline (PBS) (2  5
minutes). Nonspecific binding sites were blocked with
10% normal serum (normal horse serum for rabaptin-5
sections; normal goat serum for rab4 sections, Vector
Laboratories, Peterborough, UK) and 0.5% bovine serum
albumin in PBS for 1 hour then incubated with primary
antibody [rabaptin-5, 1:50, goat polyclonal (Santa Cruz
Biotechnology, Wiltshire, UK); rab4, 1:50, rabbit poly-
clonal (Santa Cruz)] in blocking solution overnight at 4°C.
After washing in PBS (2  5 minutes) sections were
incubated with biotinylated secondary antibody in PBS
(anti-goat IgG, 1:100 for rabaptin-5 sections; anti-rabbit
IgG, 1:100 for rab4 sections (Vector Laboratories)) for 1
hour. Sections were then washed in PBS (2  5 minutes)
and then processed with a Vectastain ABC Elite kit. Color
was developed using a 33-diaminobenzidine tetrahy-
drochloride kit (Vector Laboratories). Sections were then
dehydrated in a series of alcohols and mounted on glass
slides. Controls for the specificity of immunostaining in-
cluded omission of the primary antibody. Positive con-
trols included hippocampal sections from AD brain.
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Semiquantification of Rabaptin-5 and Rab4
Immunoreactivity
Semiquantitative assessment of rabaptin-5 and rab4 im-
munoreactivity within the hippocampus and neocortex
was performed at 200 magnification. The cases were
coded and the investigator was blind to their identity. The
degree of neuronal immunoreactivity was classified using
a scoring system as follows: 0, no neuronal staining; 1,
35% neurons stained; 2, 35 to 70% neurons stained; 3,
70% neurons stained. Glial immunoreactivity was clas-
sified similarly. Ischemic neuronal damage in hematoxy-
lin and eosin-stained sections had previously been semi-
quantified in these cases using a similar assessment to
that used above for rabaptin-5 and rab4 immunoreactiv-
ity.23 An average degree of rabaptin-5 and rab4 immu-
noreactivity and ischemic neuronal damage for each
case was calculated from the sum of the degree of neu-
ronal/glial immunoreactivity or ischemic neuronal dam-
age in CA1  CA2  CA3/CA4  dentate fascia 
neocortex  5.
Statistics
Mann-Whitney U-test for nonparametric data were used
to assess statistical significance of differences in the
degree of neuronal or glial rabaptin-5 and rab4 immuno-
reactivity between control and global ischemia groups.
The Spearman rank correlation coefficient quantified the
association of degree of neuronal rabaptin-5 or rab4
immunoreactivity with ischemic neuronal damage and
with patient survival time after global ischemia. Spearman
rank correlation analysis was also used to assess the
association between neuronal rabaptin-5 and rab4 immu-
noreactivity after global ischemia. The association of
APOE genotype with endocytosis after global ischemia
was determined for rabaptin-5 and rab4 immunoreactiv-
ity, two-way analysis of variance tested for an interaction
between the effects of presence of an APOE 4 allele
and of an episode of global ischemia. Use of two-way
analysis of variance assumes a normal distribution of data.
Assumption of normality was reasonable when the average
response per subject was calculated (Kolmogorov-Smirnov
test, P  0.05).
Results
Rabaptin-5 Immunoreactivity
Rabaptin-5 immunoreactivity was markedly increased in
neurons (Figure 1) and to a lesser extent in glia after
global ischemia. In controls, there was faint staining of
neurons and glia. In the hippocampus, neuronal staining
was predominantly confined to the pyramidal cell layer of
CA1, CA2, CA3, and CA4 and the granule cell layer of the
dentate gyrus. However, a diffuse pattern of staining
could also be seen in the molecular layer of the hip-
pocampus in some global ischemia cases. Glial staining
was more widespread in nature with a less laminar pat-
tern than the neuronal staining. Glial staining was primar-
ily astrocytic, although reactivity was also observed in
cells with the characteristic morphology of microglia.
Neuronal rabaptin-5 immunostaining was characteristi-
cally granular in nature in the cytoplasm of cell bodies
and neurites, indicative of its endosomal location. After
global ischemia, there was dense staining of rabaptin-5
adjacent to the plasma membrane (Figure 1c), whereas
in controls, when present, rabaptin-5 staining was more
widely dispersed within the cytosol (Figure 1a).
Semiquantification of the degree of rabaptin-5 immu-
noreactivity revealed significant increases in neuronal
rabaptin-5 in CA1 (P  0.0005), CA2 (P  0.0005), and
CA3/4 (P  0.0005) of the hippocampus and neocortex
(P  0.05) after global ischemia compared to controls
(Figure 2a). There was also an increase observed in the
dentate gyrus, although this was not statistically signifi-
cant. The majority of global ischemia cases showed mod-
erate to maximal neuronal rabaptin-5 immunostaining
(semiquantitative scores of 2 and 3, respectively). In
contrast, in most of the controls only minimal staining
(semiquantitative score of 1) was evident.
Glial rabaptin-5 immunostaining was detected both in
controls and after global ischemia. However, the degree
of immunoreactivity was less than that observed in neu-
rons. The majority of controls had minimal or no glial
rabaptin-5 staining present and after global ischemia
only seven cases showed a moderate or greater degree
of staining. Only in CA3/4 of the hippocampus was there
a significant increase (P  0.05) in glial rabaptin-5 after
global ischemia compared to controls (Figure 2b).
After global ischemia, rabaptin-5 immunoreactivity was
observed in nonischemic neurons and in those display-
ing the characteristic morphological features of ischemic
damage. However, there was only a small correlation
(P  0.02) between the amount of neuronal rabaptin-5
immunoreactivity and the extent of neuronal damage.
There was no association between the level of rabaptin-5
immunoreactivity and neuronal damage in controls. Fur-
thermore, there was no association between the level of
neuronal rabaptin-5 immunoreactivity and survival time of
the patients who had experienced an episode of global
ischemia (data not shown).
Rab4 Immunoreactivity
Akin to the pattern of rabaptin-5 immunoreactivity, rab4
was also detected in neurons (Figure 1) and glia. How-
ever, rab4 immunostaining showed greater intensity in
glia than rabaptin-5. Intraneuronal rab4 staining was pri-
marily restricted to the pyramidal cell layer of the hip-
pocampus and granule cell layer of the dentate gyrus
and had a granular nature in the cytoplasm of cell
bodies and neurites. Glial staining was predominantly as-
trocytic and in some cases after global ischemia intensely
stained reactive astrocytes were observed. Furthermore, in
adjacent sections stained with rab4 or rabaptin-5 it was
evident that identical regions and cells were stained with
both antibodies after global ischemia.
Rab4 immunoreactivity was observed in neurons in
global ischemia and in control cases. Semiquantification
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of the degree of neuronal rab4 immunoreactivity revealed
significant increases in CA1 (P  0.05), CA2 (P  0.05),
CA3/4 (P 0.05), and the dentate gyrus (P 0.05) of the
hippocampus and in neocortex (P  0.005) after global
ischemia compared to controls (Figure 3a). The majority
of global ischemia cases showed a moderate or greater
degree of neuronal rab4 staining whereas, in control
tissue, a minimal degree of staining was observed.
Glial rab4 immunoreactivity exhibited a similar pattern
of staining to rabaptin-5; only in one region measured,
Figure 1. Illustrative examples of neuronal rabaptin-5 (a, c, e) and rab4 (b, d, f) immunoreactivity in a patient who experienced an episode of global ischemia
(c–f) and a control patient (a, b). In the control patient, there is only faint staining of neuronal cell bodies and processes. In contrast, after global ischemia, there
is intense rabaptin-5 and rab4 immunoreactivity in the cytoplasm of neurons. All photomicrographs show CA1 of the hippocampus. Original magnifications:400
(a–d); 1000 (e, f).
Figure 2. Semiquantitative assessment of the degree of neuronal (a) and
glial (b) rabaptin-5 immunoreactivity in temporal lobe. There was a signifi-
cant increase in the level of neuronal rabaptin-5 immunoreactivity after
global ischemia compared with controls in all regions examined except the
dentate gyrus. Only in CA3/4 was there a significant change in the degree of
glial rabaptin-5 immunoreactivity after global ischemia. *, P  0.05; ***, P 
0.0005 using Mann-Whitney. Histograms are mean  SEM.
Figure 3. Semiquantitative assessment of the degree of neuronal (a) and
glial (b) rab4 immunoreactivity in temporal lobe. There was a significant
increase in neuronal rab4 immunoreactivity after global ischemia in all
regions examined. Only in CA2 of the hippocampus was there a significant
increase in glial rab4 immunoreactivity after global ischemia. *, P  0.05;
**, P  0.005 using Mann-Whitney. Histograms are mean  SEM.
276 McColl et al
AJP January 2003, Vol. 162, No. 1
CA2 (P  0.05), was there a significant increase after
global ischemia (Figure 3b). However, it was observed
that in both controls and global ischemia cases the de-
gree of glial rab4 staining was greater than rabaptin-5.
After global ischemia, the majority of cases had minimal
or moderate levels of staining, and in controls, a minimal
level was predominantly detected.
It was noted that, after global ischemia the degree of
neuronal rab4 and rabaptin-5 immunoreactivity was sim-
ilar although in controls, rab4 displayed a greater level of
staining than rabaptin-5. Correlation analysis revealed a
moderate association between neuronal rab4 and rabap-
tin-5 immunoreactivity after global ischemia (P  0.003)
(Figure 4).
As observed with rabaptin-5, rab4 immunoreactivity
was observed in both nonischemic and ischemic neurons
after global ischemia. However, there was no association
between the degree of neuronal rab4 immunoreactivity
and ischemic neuronal damage after global ischemia. In
addition, there was no correlation between neuronal rab4
immunoreactivity and survival time of global ischemia
patients.
Association of APOE Genotype with Changes in
Degree of Neuronal Rabaptin-5 and Rab4
Immunoreactivity after Global Ischemia
(Figures 5 and 6)
We tested the hypothesis that APOE genotype may be
associated with changes in the degree of neuronal
rabaptin-5 and rab4 immunoreactivity. The cases were
separated into those that contained at least one APOE 4
allele and those without an 4 allele. The number of
individuals homozygous for the APOE 4 allele was too
low to evaluate whether this genotype was associated
with the parameters measured (two controls and two
global ischemia cases were 4 homozygotes). Likewise,
the frequency of the 2 allele was too low to determine
any associations this allele may have (two controls and
three global ischemia cases had one 2 allele; there were
no control or global ischemia 2 homozygotes). An aver-
age degree of neuronal rabaptin-5 and rab4 immunore-
activity was calculated based on the levels assessed in
hippocampal sectors CA1, CA2, CA3/4, dentate fascia,
and neocortex. Two-way analysis of variance showed
that the degree of rabaptin-5 immunoreactivity was not
significantly different between the APOE 4 and non-4
allele groups (P  0.62) but was significantly greater in
the global ischemia group than the control group (P 
0.001). There was no significant interaction between
presence of the 4 allele and global ischemia (P  0.98).
Two-way analysis of variance revealed that the degree of
rab4 immunoreactivity was not significantly different be-
tween the APOE 4 and non-4 groups (P  0.62) and
was not significantly different between the control and
global ischemia groups (P 0.10). However, there was a
Figure 4. Association between the degree of neuronal rabaptin-5 and rab4
immunoreactivity after global ischemia. There was a positive association
between the degree of rabaptin-5 and rab4 immunoreactivity after global
ischemia. (P  0.003 using Spearman’s rank correlation analysis) Note: 43
data points were plotted, however, several points are superimposed there-
fore fewer data points are visible.
Figure 5. The average degree of neuronal rabaptin-5 immunoreactivity in
temporal lobe in cases with and without an APOE 4 allele. Using two-way
analysis of variance, the degree of rabaptin-5 immunoreactivity was not
significantly different between the APOE 4 and non-4 groups (P  0.62)
but was significantly greater in the global ischemia group than the control
group (P  0.001). There was no significant interaction between the pres-
ence of an 4 allele and global ischemia (P  0.98). Histograms are mean 
SEM. Average calculated from sum of CA1  CA2  CA3/4  dentate gy-
rus  neocortex  5.
Figure 6. The average degree of neuronal rab4 immunoreactivity in tempo-
ral lobe in cases with and without an APOE 4 allele. Using two-way analysis
of variance, the degree of rab4 immunoreactivity was not significantly dif-
ferent between the APOE 4 and non-4 groups (P  0.62) and was not
significantly different between the control and global ischemia groups (P 
0.10). There was a significant interaction between the presence of an 4 allele
and global ischemia (P  0.017). Histograms are mean  SEM. Average calcu-
lated from sum of CA1  CA2  CA3/4  dentate gyrus  neocortex  5.
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significant interaction between presence of an 4 allele
and an episode of global ischemia (P  0.017). The
mean increase in rab4 immunoreactivity after global isch-
emia was 0.9 units lower on the semiquantitative score in
patients with 4 than in non-4 patients (with a 95%
confidence interval of 0.2 to 1.6 units lower).
A Deposition and Neurofibrillary Tangles
In all cases, the presence of A deposits and neurofibril-
lary tangles was determined using sections immuno-
stained with anti-amyloid and anti-tau antibodies. A mi-
nority of controls and global ischemia patients displayed
A deposits and neurofibrillary tangles. Four controls had
amyloid deposits alone and one control displayed both
amyloid deposits and neurofibrillary tangles. In the global
ischemia group, five cases had amyloid deposits and two
had both amyloid deposits and tangles. There was no
association between APOE genotype and the presence
of amyloid deposits or tangles in both controls and global
ischemia individuals. Furthermore, the presence of amy-
loid deposits or tangles was not associated with in-
creased levels of rabaptin-5 or rab4 immunoreactivity.
Discussion
This is the first demonstration of alterations in the endo-
cytic pathway of neurons and glia after global ischemia in
humans. We have shown that rabaptin-5 and rab4 immu-
noreactivity is increased in neurons and to a limited ex-
tent in glia in the hippocampus and neocortex of medial
temporal lobe after global ischemia compared to normal
controls. Rabaptin-5 and rab4 are markers of endocytic
pathway activity and therefore, these results indicate an
up-regulation of the intracellular trafficking process in
neurons and glia of brains subject to an episode of global
ischemia. Furthermore, we report an APOE genotype dif-
ference in endocytic pathway alterations after global
ischemia.
The patients in this study experienced an episode of
global ischemia caused by cardiac arrest with subse-
quent cerebral reperfusion. It should be noted that con-
trols might have some extent of terminal hypoxia and/or
hypotension because most die from a cardiac arrest but
this would also be true of the global ischemia cases.
However, in controls, reperfusion is not occurring. Fur-
thermore, in a previous study using this cohort of individ-
uals, there was minimal evidence of ischemic neuronal
damage in control patients.23 In humans, an episode of
global ischemia with subsequent reperfusion results in a
relatively stereotyped pathology in which there is selec-
tive neuronal damage in the hippocampus and neocor-
tex.24 In AD, in which neuronal injury is also a predomi-
nant feature, alterations in the neuronal endocytic
pathway have previously been reported.12 This suggests
that the cascade of events after neuronal damage may
include changes in the trafficking of molecules from the
plasma membrane through the endocytic system. In cor-
tical pyramidal neurons from AD brain, early endosomal
volume was significantly increased in neurons labeled
with antibodies to rab5 and rabaptin-5. In addition, ele-
vated rab4 immunoreactivity was observed in pyramidal
neurons in the frontal cortex of AD brain. These observa-
tions are believed to indicate an increase in endocytic
pathway activity because overexpression of rab 5, rabap-
tin-5, and rab4 have all been shown to promote increased
endocytosis.8,25–27 In the present study, neuronal rabap-
tin-5 and rab4 immunoreactivity was markedly increased
in all regions examined in the temporal lobe of patients
after global ischemia. This suggests that neuronal dam-
age caused by an episode of global ischemia may be
precipitating these increases in endocytic activity. How-
ever, minimal rabaptin-5 and rab4 immunoreactivity was
also detected in neurons from control brain. Furthermore,
there was no association between ischemic neuronal
damage and the degree of either neuronal rabaptin-5 or
rab4 immunoreactivity. A possible explanation for these
observations is that endocytic alterations appear at a
very early stage of neuronal damage and therefore may
be detected before there is morphological evidence of
ischemic neurons. Endosomal alterations are present in
cortical pyramidal neurons of young patients with Down
syndrome,12 before the development of neurofibrillary
tangles and amyloid deposits and the onset of neurode-
generation. It is conceivable, therefore, that endocytic
pathway alterations are a very early response before
neuronal damage can be visualized histologically.
The results from this study suggest that overall endo-
cytic pathway activity is increased after global ischemia.
Furthermore, the two distinct stages of endocytosis la-
beled by antibodies to rabaptin-5 and rab4, enable sep-
aration of the responses of these two phases of endoso-
mal trafficking. Rabaptin-5 localizes to early endosomes
and therefore an increase in rabaptin-5 immunoreactivity
in neurons is indicative of an increase in the internaliza-
tion and trafficking of material from the neuronal plasma
membrane to early endosomes. In contrast, rab4 local-
izes to recycling endosomes that are returning to the
plasma membrane and, consequently, an increase in
immunostaining with rab4 antibody suggests an increase
in transport of material back to the plasma membrane.
Therefore, there is evidence of a parallel response of the
internalization and recycling stages of endocytosis in
neurons after global ischemia. This is supported by our
finding of an association between neuronal rabaptin-5
and rab4 immunoreactivity after global ischemia (r2 
0.24, P  0.003).
When patients were separated into groups based on
APOE genotype, there were two notable observations.
First, we determined that there was a statistically signifi-
cant influence of APOE genotype on the degree of rab4
immunoreactivity changes in response to global isch-
emia. In contrast, there was no APOE genotype influence
on the degree of rabaptin-5 immunoreactivity changes in
response to global ischemia. This indicates that there is a
differential response of the early trafficking and recycling
stages of endocytosis after global ischemia in APOE 4
and non-4 individuals. Second, the data indicate a trend
toward an increase in neuronal rab4 immunoreactivity in
the APOE 4 control group, suggestive of underlying
differences in endocytic pathway activity in control brain.
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Up-regulation of recycling activity as a consequence of
early AD is unlikely, because we found no evidence that
the presence of amyloid deposits and/or neurofibrillary
tangles influenced the extent of endosomal recycling. In
individuals with amyloid deposits and/or tangles, we
found no association with APOE genotype or levels of
immunoreactivity of our endocytic markers. Higher levels
of rab4 immunoreactivity in the control 4 group may
reflect APOE isoform-specific intrinsic differences in en-
dosomal trafficking. In previous studies, APOE genotype
has been shown to influence other aspects of general
brain function in uninjured brain, such as cerebral glu-
cose metabolism.28 Cell culture studies have demon-
strated isoform-specific differences in cellular trafficking
and localization of apoE in uninjured neurons. DeKroon
and Armati29 have shown that cultured human brain neu-
rons incubated with apoE E3 or E4 traffic each isoform in
a different manner. ApoE E3 and E4 have been demon-
strated to accumulate in different parts of the neuron and
show variation in interaction with cellular proteins.30,31
Isoform-specific effects influencing cellular physiology in
uninjured brain may therefore underlie the apparent dis-
crepancy in endocytic recycling activity between the two
control groups, an important finding in itself. It should
also be noted that the APOE isoform-specific effects de-
scribed above, in both controls and global ischemia
cases, are unlikely to simply be a reflection of differences
in the degree of neuronal damage. In a previous study
using this cohort of patients, possession of an APOE 4
allele did not influence the degree of neuronal damage
after global ischemia or in controls.23
It is possible that an APOE genotype influence on
outcome after brain injury is mediated through endocytic
pathway interactions. Neurons use endocytosis to take
up many important macromolecules from the extracellu-
lar environment, including lipids and cholesterol. Lipids
are particularly important building blocks of neuronal
plasma membranes and myelin sheaths of axons. In the
central nervous system, apoE acts as a lipid transport
protein to deliver bound lipids to cells.32,33 Sites in the
amino-terminal domain interact with plasma membrane
receptors, such as the low-density lipoprotein receptor-
related protein (LRP), to facilitate internalization of the
apoE-lipid-receptor complex. After neuronal damage, ef-
ficient delivery and uptake of lipid molecules is likely to
enhance neuronal repair and survival34 and this requires
a maximally operational endocytic pathway. Our data
demonstrate a differential response of the endocytic
pathway to global ischemia in 4 and non-4 individuals.
In 4 individuals, there is a trend toward a reduced num-
ber of endosomes being recycled back to the plasma
membrane after global ischemia, compared to non-4
individuals in which there is a trend toward increased
activity. An increase in the internalization and trafficking
of molecules to early endosomes would facilitate in-
creased uptake of lipids into the neuronal cytoplasm
where they can be directed for membrane integration.
After early endosomes have released cargo destined for
other sites in the neuron, such as lipids, they can return to
the plasma membrane and in turn recycle apoE and LRP
for subsequent reuse. If there are fewer endosomes be-
ing recycled, there will be a resultant reduction in the
amount of apoE and LRP recycled that may result in
impaired uptake of lipids. Consequently, membrane re-
organization and repair may be less effective in APOE 4
patients, which is likely to have a major influence on
outcome to injury.
Membrane rebuilding is an integral part of brain plas-
ticity requiring both adequate supply and uptake of lip-
ids. We have described how lipid uptake may be com-
promised in 4 individuals after global ischemia. The role
of apoE in the scavenging and delivery of lipids to neu-
rons has previously been shown to be an integral com-
ponent of the neuronal repair process.35,36 ApoE is
thought to scavenge and transport large quantities of
lipids and cholesterol released from degenerating axon
membranes and myelin37,38 and deliver these to dam-
aged but surviving neurons for repair. In vitro studies
have demonstrated that the apoE E3 isoform is more
effective in promoting neuronal survival and neurite out-
growth than apoE E4.30,39 It is possible, therefore, that
individuals with an APOE 4 allele will have impaired
delivery of lipids and cholesterol to neurons in addition to
a compromised ability to internalize these molecules after
brain injury.
Findings from in vitro studies investigating the transport
of apoE isoforms through the endocytic pathway have
further emphasized the significance of apoE isoform-
specific variations in endocytic behavior. Using marker
molecules for different compartments of the endocytic
system, progression of apoE E3 and apoE E4 through
these compartments was shown to be different.29 Al-
though both isoforms were trafficked similarly through
early endosomes, subsequently, apoE E4 was localized
to late endosomes and lysosomes, whereas there was
little evidence of apoE E3 after this route. This is intriguing
as it suggests that apoE E3 may follow a recycling path-
way back to the plasma membrane along with its asso-
ciated low-density LRP. Such a route would enhance the
lipid delivery system during neuronal repair and is con-
sistent with our finding that endosomal recycling is in-
creased in APOE 3 patients after global ischemia.
Thus far, we have proposed that endocytic pathway
alterations may be involved in repair processes after
brain injury. It is also possible these changes are involved
in neuronal death/apoptotic pathways, although our find-
ing of a lack of association of rabaptin-5 and rab4 stain-
ing with the extent of neuronal damage would argue
against this. However, this cannot exclude the possibility
that endosomal alterations are an early response before
neuropathological evidence of neuronal death appears,
as we discussed above. Previously, after neuronal injury,
the lysosomal system was shown to be up-regulated
before the appearance of histological and biochemical
markers of neuronal death.40
The results from this study may also be of relevance to
AD. The endocytic pathway is a key point of convergence
for several molecules implicated in AD pathogenesis,
such as amyloid precursor protein, A, apoE, and the
LRP.12 As already discussed, endosomal alterations in
neurons of young patients with Down syndrome have
been observed. It is possible that alterations in the endo-
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cytic pathway contribute to changes in neuronal pro-
cesses years before the onset of clinical signs of AD.
Such alterations could affect the normal interactions and
trafficking of molecules such as apoE, LRP, and amyloid
precursor protein with detrimental consequences on neu-
ronal function. Furthermore, a genetic influence mediated
by APOE polymorphism may underlie changes observed
in endocytosis. Our results would suggest that posses-
sion of the 4 allele is associated with a reduced capacity
for endocytic adaptations that promote neuronal repair. It
has been proposed that individuals with an APOE 4
allele have a reduced ability to compensate for age-
related neuronal loss41 and in patients with AD, plastic
neuronal remodeling was shown to be impaired in indi-
viduals carrying an 4 allele.42 APOE genotype-specific
effects on endocytic function may be involved in pro-
cesses underlying these observations.
This study highlights a role for the endocytic system in
the response to brain injury. However, there is a need for
further investigation of how the pathway functions in both
normal and disease states. Additionally, elucidation of
the interactions between endocytosis and molecules im-
plicated in acute brain injury and AD pathophysiology,
such as apoE and A are required.
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